Estimate prognosis in myelofibrosis.
The DIPSS was proposed and validated by Passamonti et al to estimate prognosis in myelofibrosis.
The DIPSS plus score further refines the prior prognostic scoring system with the addition of DIPSS-independent risk factors, including karyotype, transfusion dependency and platelet count. The score was developed and validated by Gangat et al.
Prognosis based on 6 point scoring system:
Gangat et al.
Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2011 February 1, 29 (4): 392-7
Passamonti et al.
Blood 2010 March 4, 115 (9): 1703-8
© 2020 QxMD Software Inc., all rights reserved. No part of this service may be reproduced in any way without express written consent of QxMD. This information should not be used for the diagnosis or treatment of any health problem or disease. This information is not intended to replace clinical judgment or guide individual patient care in any manner. Click here for full notice and disclaimer.